Your GLP-1 Is Doing More to Your Brain Than You Think
Your brain runs on a currency called dopamine, and the system that produces it is called the mesolimbic pathway, which is the brain's way of deciding what is worth pursuing and what is not.
The pathway works like this: a region deep in the midbrain called the ventral tegmental area, or VTA, manufactures dopamine and ships it forward to a structure called the nucleus accumbens, which then translates that signal into motivation and drive. When you see something your brain has marked as rewarding, the VTA fires, dopamine floods the nucleus accumbens, and you feel pulled toward the thing. That pull is what researchers call "wanting," and it is what gets you out of your chair to pursue something, whether that is food, sex, a drink, or anything else your brain has learned to value.
Now here is where GLP-1 drugs enter the picture.
GLP-1 receptors are not just in your gut. They sit directly inside the VTA, embedded in neurons that do not make dopamine but instead produce something called GABA, which is the brain's primary inhibitory signal. GABA neurons are essentially the brake pedal on dopamine neurons. When GABA neurons fire, they suppress dopamine output. When they go quiet, dopamine flows more freely.
A 2025 study published in Science Advances demonstrated exactly this: GLP-1 receptor activation in the VTA increases the firing rate of those GABA neurons, which then suppresses dopamine neuron activity and attenuates reward-seeking behavior in animal models. The drug is pressing the brake on dopamine before it even leaves the factory.
The downstream effect is a reduction in wanting, and the distinction between wanting and liking matters here because most people assume they are the same thing.
Wanting is the motivational drive to pursue a reward before you have it. Liking is the hedonic pleasure you experience in the moment you receive it. These two processes are neurologically separate, and GLP-1 drugs appear to affect one without affecting the other. Research on semaglutide found that while the drug reduced reward-seeking and collection behavior, it did not diminish the hedonic response once the reward was actually received. The consummatory experience itself remained intact.
This is what makes the side effect nearly invisible while you are living inside it.
If sex stopped feeling good, you would notice. If your mood dropped or your emotional baseline shifted, you would have a signal. But if what diminishes is only the initiation, only the thought that prompts you to reach toward something, you have nothing to compare against. Your brain is not generating the signal that would tell you something is missing. The absence of wanting does not feel like loss. It just feels like quiet.
That is the trap. And it is why people do not realize what has changed until they come off the drug and the drive returns with a contrast they could not have predicted.
On top of the dopamine pathway, there is a second proposed mechanism running simultaneously. A 2025 clinical review in Obesity Pillars put forward that GLP-1 agonists likely increase activity at a specific serotonin receptor called the 5-HT2C receptor, which is the same receptor that produces sexual side effects in SSRIs. The authors are careful to call this a proposed mechanism rather than an established one, but the implication is that two separate systems may both be suppressing desire at the same time, one through dopamine inhibition and one through serotonergic modulation.
The review also points to something that makes this harder to detect at the population level: weight loss itself improves sexual function, body image, and confidence in ways that can mask the libido suppression happening underneath. A person who loses 30 pounds on semaglutide and reports feeling better about sex overall is not wrong, but the drug may still be pulling in the opposite direction without the net result making that visible.
The reward pathway modulation extends well beyond sex. A randomized clinical trial published in JAMA Psychiatry in 2025 tested semaglutide in 48 adults with alcohol use disorder and found significant reductions in alcohol craving, consumption, and heavy drinking days. This is not a metabolic effect. GLP-1 is not changing how alcohol is absorbed or processed. It is changing how the brain weighs the value of the reward itself. The VTA mechanism that suppresses appetite appears to suppress the wanting signal across reward categories.
For the person trying to understand their own experience on these drugs, the practical question is what to do with this information.
The most straightforward answer is that if you have noticed reduced initiation, reduced interest in things that used to pull you forward, or a partner who has observed the change before you did, the pharmacology gives you a direct explanation. This is not motivational dysfunction or relationship drift. It is GLP-1 receptors in the VTA pressing the brake on the mesolimbic pathway, and it is doing it without your awareness because the signal that would alert you to the problem is the exact signal being suppressed.
These drugs have a half-life of approximately one week, which means active drug levels drop substantially within a week of stopping and reach baseline within roughly four to five weeks. The reward signaling returns. The wanting comes back. The switch gets flipped in the other direction, and that is when people can finally see what had been muted.
The null result from a four-week dulaglutide study in healthy men, which found no change in sexual function scores, is worth noting here. Dulaglutide penetrates the central nervous system less effectively than semaglutide and the study ran for only four weeks, so it may be measuring the wrong drug at the wrong duration rather than telling us the mechanism does not operate.
The deeper issue this whole picture reveals is that appetite and desire and motivation are not separate systems running in parallel. They are different outputs from the same underlying circuit, the wanting circuit, and a drug that modulates one will modulate the others. That is not a flaw in the drug's design. It is just how the brain is built.
References
- Merkel R, Thapa N, Engel L, et al. 2025. An endogenous GLP-1 circuit engages VTA GABA neurons to regulate mesolimbic dopamine neurons and attenuate cocaine seeking. Science Advances, 119, eadr5051. Finding: GLP-1 receptor activation in the VTA increases GABA neuron firing, which suppresses dopamine neuron activity and reduces reward-seeking behavior. Source
- Hurst K, et al. 2025. GLP-1 receptor agonist semaglutide reduces appetite while increasing dopamine reward signaling. Neurobiology of Disease and Treatment. Finding: Semaglutide reduced reward collection but did not diminish hedonic "liking" response, and actually enhanced VTA dopamine activity during consummatory phase. Source
- Gelfand SG, Tveit RL, Simon JA. 2026. Clinical review of how glucagon-like peptide-1 agonist obesity medications decrease sexual desire, and a biopsychosocial model for why we don't 'see' it. Obesity Pillars, 17, 100233. Finding: GLP-1 agonists likely decrease sexual desire via 5-HT2C serotonergic upregulation same mechanism as SSRIs, but this is camouflaged by competing positive effects of weight loss. Source
- Hendershot CS, et al. 2025. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry, 824, 395-405. Finding: Semaglutide reduced alcohol consumption, craving, and heavy drinking days in a Phase 2 RCT n=48, confirming reward pathway modulation extends beyond appetite. Source
- Jalleh RJ, et al. 2024. Effects of the glucagon-like peptide-1 receptor agonist dulaglutide on sexuality in healthy men: a randomised, double-blind, placebo-controlled crossover study. eBioMedicine, 107. Finding: 4-week dulaglutide in healthy eugonadal men showed no change in sexual function scores null result, but short duration and weaker CNS penetration than semaglutide. Source
Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness
If this is the kind of information you want access to on a daily basis, the community is free and there are full courses on training, nutrition, hormones, and supplementation inside. You can ask questions and post your own labs and get feedback from me and from the community.